Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Dokumenty

Y0000492

Oxycodone hydrochloride

European Pharmacopoeia (EP) Reference Standard

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C18H21NO4 · HCl
Numer CAS:
124-90-3
Masa cząsteczkowa:
351.82
Numer MDL:
MFCD00137583
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329830982
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

oxycodone

producent / nazwa handlowa

EDQM

kontrola substancji

USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

Zastosowanie

pharmaceutical (small molecule)

format

neat

temp. przechowywania

2-8°C

ciąg SMILES

Cl.[H][C@@]12Oc3c(OC)ccc4C[C@H]5N(C)CC[C@@]1(c34)[C@@]5(O)CCC2=O

InChI

1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

Klucz InChI

MUZQPDBAOYKNLO-RKXJKUSZSA-N

informacje o genach

human ... OPRM1(4988)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Oxycodone hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Działania biochem./fizjol.

μ and κ opioid receptor agonist.

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Sales restrictions may apply.

produkt powiązany

Numer produktu
Opis
Cennik

Y0000453

Oxycodone impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000723

Thebaine, European Pharmacopoeia (EP) Reference Standard

1485191

Oxycodone, United States Pharmacopeia (USP) Reference Standard

1485216

Oxycodone Related Compound A, United States Pharmacopeia (USP) Reference Standard

1485205

Oxycodone hydrochloride, United States Pharmacopeia (USP) Reference Standard

1485238

Oxycodone Related Compound C, United States Pharmacopeia (USP) Reference Standard

1485227

Oxycodone Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP1068

Oxycodone hydrochloride, British Pharmacopoeia (BP) Reference Standard

BP1136

Oxycodone impurity standard, British Pharmacopoeia (BP) Reference Standard

Piktogramy

Exclamation mark
GHS07

Hasło ostrzegawcze

Warning

Zwroty wskazujące rodzaj zagrożenia

H302,H336

Zwroty wskazujące środki ostrożności

P261 - P264 - P270 - P271 - P301 + P312 - P304 + P340 + P312

Klasyfikacja zagrożeń

Acute Tox. 4 Oral - STOT SE 3

Organy docelowe

Central nervous system

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Choose from one of the most recent versions:

Certyfikaty analizy (CoA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Salvatore V Colucci et al.
Clinical drug investigation, 34(6), 421-429 (2014-04-24)
Abuse of opioid analgesics has become a public health issue. Some opioid abusers use intravenous administration to increase the magnitude of positive reinforcing effects. Intravenous co-administration of oxycodone with naloxone, an opioid antagonist, may reduce these rewarding effects and discourage
Caitlin M Vander Weele et al.
The European journal of neuroscience, 40(7), 3041-3054 (2014-09-12)
While most drugs of abuse increase dopamine neurotransmission, rapid neurochemical measurements show that different drugs evoke distinct dopamine release patterns within the nucleus accumbens. Rapid changes in dopamine concentration following psychostimulant administration have been well studied; however, such changes have
Carrie L Wade et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(2), 421-428 (2014-07-26)
The abuse of prescription opioids that are used for the treatment of chronic pain is a major public health concern, costing ∼$53.4 billion annually in lost wages, health-care costs, and criminal costs. Although opioids remain a first-line therapy for the
Jason A Miranda et al.
PloS one, 9(8), e106108-e106108 (2014-08-27)
Sensory processing in the spinal cord during disease states can reveal mechanisms for novel treatments, yet very little is known about pain processing at this level in the most commonly used animal models of articular pain. Here we report a
Tomoe Kanbara et al.
Neuroscience letters, 580, 119-124 (2014-08-17)
It has begun to be understood that μ-opioid receptor (MOR) produces ligand-biased agonism, which contributes to differential physiological functions of MOR agonists. We previously demonstrated that in oxaliplatin-induced neuropathy in rats, morphine and oxycodone exhibited antinociceptive effects while antinociception of
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej